Retatrutide

Eli Lilly's experimental drug Retatrutide shows promising secondary kidney health benefits in a phase 2 trial, significantly reducing urinary protein, blood pressure, and weight.

A groundbreaking weight-loss drug, Retatrutide, offers high efficacy in clinical trials but triggers severe medical warnings regarding gray-market counterfeits.

Eli Lilly is launching an early access program for Retatrutide, a promising weight-loss drug that has shown record-breaking results in clinical trials. The move follows concerns over a black market for counterfeits.